“Common Warts Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Common Warts Market.
The Common Warts Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Common Warts Pipeline Report:
Companies across the globe are diligently working toward developing novel Common Warts treatment therapies with a considerable amount of success over the years.
Common Warts companies working in the treatment market are Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others, are developing therapies for the Common Warts treatment
Emerging Common Warts therapies in the different phases of clinical trials are- CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others are expected to have a significant impact on the Common Warts market in the coming years.
In May 2025, Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced progress in its late-stage development pipeline, highlighted by the completion of an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for VP-315, the company’s investigational treatment for basal cell carcinoma. Additionally, Verrica is making strides toward launching a global Phase 3 clinical program for VP-102/YCANTH, its treatment candidate for common warts, in collaboration with its partner, Torii Pharmaceutical.
In February 2025, Nielsen BioSciences, Inc., a privately held biopharmaceutical company headquartered in San Diego, announced the successful enrollment of the final participant in its Phase 3 clinical trial, CFW-3A. This randomized, double-blind, placebo-controlled study is evaluating the safety and efficacy of CANDIN® (Candida albicans Skin Test Antigen for Cellular Hypersensitivity) for treating common warts (Verruca vulgaris) in both adolescents and adults. It’s important to note that CANDIN is not yet approved for this indication.
In December 2024, Veradermics was a late-stage clinical biopharmaceutical company specializing in aesthetics and dermatology, dedicated to developing innovative therapies for common skin disorders. Its leading product, VDPHL01, is a non-hormonal oral treatment currently being tested for androgenetic alopecia (AGA) and pattern hair loss (PHL) in both male and female patients. Additionally, the company’s pipeline features treatments targeting widespread dermatological conditions like warts and molluscum contagiosum.
In August 2024, Verrica Pharmaceuticals reported encouraging new findings from its Phase 2 trial of the oncolytic peptide VP-315 for basal cell carcinoma treatment. With positive safety and efficacy outcomes, the company sees VP-315 as a potential first-line therapy for this cancer type. Comprehensive results will be shared at an upcoming KOL event. Furthermore, Verrica has revised its agreement with Torii Pharmaceutical Inc. Ltd., supporting the progression of YCANTH into Phase 3 trials for common warts. Addressing a significant unmet need in dermatology, YCANTH has the potential to become a new standard of care, as no FDA-approved treatments currently exist for common warts.
In May 2024, Verrica Pharmaceuticals announced an update to its collaboration and licensing agreement with Torii Pharmaceutical Co. Ltd. to jointly fund the global Phase 3 clinical trial for YCANTH® targeting common warts. According to the revised terms, both companies will equally share the trial expenses, with Torii covering Verrica’s share by offsetting future payments related to regulatory milestones and sales of YCANTH for molluscum contagiosum and common warts in Japan. Furthermore, Torii will make an $8.0 million milestone payment to Verrica upon dosing the first patient in Japan, with the Phase 3 trial expected to commence in the first half of 2025.
Common Warts Overview
Common warts are small, noncancerous skin growths caused by the human papillomavirus (HPV). They typically appear on the hands, fingers, or other areas prone to minor cuts and abrasions. Common warts have a rough, grainy texture and are often flesh-colored, with tiny black dots (clotted blood vessels) on the surface.
Get a Free Sample PDF Report to know more about Common Warts Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/common-warts-pipeline-insight
Emerging Common Warts Drugs Under Different Phases of Clinical Development Include:
CANDIN: Nielsen BioSciences/Maruho
VP-102: Verrica Pharmaceutical
FIT039: Kino Pharma/ Iwaki Pharmaceutical
A-101: Aclaris Therapeutics, Inc.
KNP2002: KinoPharma Inc.
10% EISO: ViroXis Corporation
CLS006: Maruho Co., Ltd.
VDMN-21: Veradermics, Inc.
Resiquimod: Graceway Pharmaceuticals, LLC
Imiquimod: MEDA Pharma
Picato: LEO Pharma
Common Warts Route of Administration
Common Warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Common Warts Molecule Type
Common Warts Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Common Warts Pipeline Therapeutics Assessment
Common Warts Assessment by Product Type
Common Warts By Stage and Product Type
Common Warts Assessment by Route of Administration
Common Warts By Stage and Route of Administration
Common Warts Assessment by Molecule Type
Common Warts by Stage and Molecule Type
DelveInsight’s Common Warts Report covers around 5+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Common Warts product details are provided in the report. Download the Common Warts pipeline report to learn more about the emerging Common Warts therapies
Some of the key companies in the Common Warts Therapeutics Market include:
Key companies developing therapies for Common Warts are – Nielsen BioSciences, Veloce BioPharma, Verrica Pharmaceutical, Maruho Co., Aclaris Therapeutics, and others.
Common Warts Pipeline Analysis:
The Common Warts pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Common Warts with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Common Warts Treatment.
Common Warts key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Common Warts Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Common Warts market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Common Warts drugs and therapies
Common Warts Pipeline Market Strengths
The rising prevalence of warts is encourages companies in the life sciences industry to focus on research and development of new drugs for warts treatment. There is a continuous need for new, innovative therapeutic approaches for better treatment outcomes.
An increase in emerging new drugs for the treatment of warts will lead to better patient outcomes in the coming years.
Common Warts Pipeline Market Opportunities
Recent studies have shown the safe and efficacious role of Zinc supplementation in warts clearance, particularly for patients who have not responded to treatments previously.
Secondary research on the warts therapeutics market suggests that the market is saturated with limited drug opportunities providing the key Pharma players a successful domain to work with utmost robustness
Scope of Common Warts Pipeline Drug Insight
Coverage: Global
Key Common Warts Companies: Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others
Key Common Warts Therapies: CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others
Common Warts Therapeutic Assessment: Common Warts current marketed and Common Warts emerging therapies
Common Warts Market Dynamics: Common Warts market drivers and Common Warts market barriers
Request for Sample PDF Report for Common Warts Pipeline Assessment and clinical trials
Table of Contents
1. Common Warts Report Introduction
2. Common Warts Executive Summary
3. Common Warts Overview
4. Common Warts- Analytical Perspective In-depth Commercial Assessment
5. Common Warts Pipeline Therapeutics
6. Common Warts Late Stage Products (Phase II/III)
7. Common Warts Mid Stage Products (Phase II)
8. Common Warts Early Stage Products (Phase I)
9. Common Warts Preclinical Stage Products
10. Common Warts Therapeutics Assessment
11. Common Warts Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Common Warts Key Companies
14. Common Warts Key Products
15. Common Warts Unmet Needs
16 . Common Warts Market Drivers and Barriers
17. Common Warts Future Perspectives and Conclusion
18. Common Warts Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
